Bill Harriman - OmniAb Senior Discovery
| OABI Stock | USD 3.90 0.12 3.17% |
Executive
Bill Harriman is Senior Discovery of OmniAb Inc
| Address | 5980 Horton Street, Emeryville, CA, United States, 94608 |
| Phone | 510 250 7800 |
| Web | https://www.omniab.com |
OmniAb Management Efficiency
The company has return on total asset (ROA) of (0.1376) % which means that it has lost $0.1376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2045) %, meaning that it created substantial loss on money invested by shareholders. OmniAb's management efficiency ratios could be used to measure how well OmniAb manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.39. The current Return On Capital Employed is estimated to decrease to -0.21. As of now, OmniAb's Other Assets are increasing as compared to previous years. The OmniAb's current Intangibles To Total Assets is estimated to increase to 0.87, while Total Assets are projected to decrease to under 364.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Ticktin | Pmv Pharmaceuticals | 62 | |
| B ASIA | Verona Pharma PLC | 57 | |
| Julie Dexter | Olema Pharmaceuticals | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| John MBA | Vor Biopharma | 48 | |
| Sue Browne | Passage Bio | N/A | |
| Chandra MS | Erasca Inc | 53 | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Robin Wagner | Keros Therapeutics | N/A | |
| MSc MD | Bioatla | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Amy Quinlan | Vor Biopharma | 49 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Bin Zhang | Bioatla | N/A | |
| Samir MS | Vor Biopharma | N/A | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Guowei Fang | Legend Biotech Corp | N/A | |
| Steven Gavel | Legend Biotech Corp | N/A | |
| Stu Dorman | Ideaya Biosciences | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Esq JD | Erasca Inc | 52 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.14 |
OmniAb Inc Leadership Team
Elected by the shareholders, the OmniAb's board of directors comprises two types of representatives: OmniAb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OmniAb. The board's role is to monitor OmniAb's management team and ensure that shareholders' interests are well served. OmniAb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OmniAb's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cia McCaffrey, Vice Talent | ||
| Donna CPA, Senior Controller | ||
| Bill Harriman, Senior Discovery | ||
| Douglas Krafte, Senior Head | ||
| Kurt Gustafson, Executive CFO | ||
| MarieCecile DVM, Senior Genetics | ||
| Charles JD, Chief Secretary | ||
| Christel Iffland, Senior Technologies | ||
| Matthew Foehr, CEO President |
OmniAb Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OmniAb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (4.74) % | ||||
| Current Valuation | 436.41 M | ||||
| Shares Outstanding | 121.01 M | ||||
| Shares Owned By Insiders | 5.88 % | ||||
| Shares Owned By Institutions | 68.98 % | ||||
| Number Of Shares Shorted | 7.37 M | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 23.12 X |
Currently Active Assets on Macroaxis
When determining whether OmniAb Inc is a strong investment it is important to analyze OmniAb's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact OmniAb's future performance. For an informed investment choice regarding OmniAb Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OmniAb Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OmniAb. If investors know OmniAb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OmniAb listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.24) | Return On Assets (0.14) | Return On Equity (0.20) |
The market value of OmniAb Inc is measured differently than its book value, which is the value of OmniAb that is recorded on the company's balance sheet. Investors also form their own opinion of OmniAb's value that differs from its market value or its book value, called intrinsic value, which is OmniAb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OmniAb's market value can be influenced by many factors that don't directly affect OmniAb's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OmniAb's value and its price as these two are different measures arrived at by different means. Investors typically determine if OmniAb is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OmniAb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.